Top

Published in:

01-01-2021 | COVID-19 | Original Article

Characteristics of coagulation alteration in patients with COVID-19

Authors: Hong-chun Luo, Cheng-yan You, Si-wei Lu, Yue-qiang Fu

Published in: Annals of Hematology | Issue 1/2021

Abstract

Abnormal blood coagulation often occurs in critically ill patients, which seriously affects their prognosis. This retrospective study investigated the implications of changes in blood coagulation in patients with coronavirus disease 2019 (COVID-19). Records were reviewed for patients admitted with COVID-19 between February 4 and 16, 2020. The primary outcome was in-hospital death. A total of 85 patients were included, of whom 12 died in the hospital. The admission prothrombin time (PT), international normalized ratio (INR), and levels of D-dimer and fibrin/fibrinogen degradation products (FDP) were significantly higher in non-survivors than in survivors, while the reverse was true for prothrombin time activity (PT-act) and PaO₂/FiO₂. Multivariate logistic regression showed that PT-act < 75% was independently associated with mortality. The area under the receiver operating characteristic curves for PT-act, D-dimer, and FDP at admission could significantly predict mortality. The AUCs for PT-act were larger than those for D-dimer and FDP; however, there was no significant difference. After 2 weeks of treatment, the coagulation parameters of the surviving patients improved. COVID-19 is often accompanied by abnormal coagulation. PT-act at admission is able to predict mortality in patients with COVID-19 as can D-dimer and FDP levels. PT-act < 75% is independently associated with mortality.

Idell S (2003) Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 31(4 Suppl):S213–S220. https://doi.org/10.1097/01.CCM.0000057846.21303.ABCrossRefPubMed

Welty-Wolf KE, Carraway MS, Ortel TL, Piantadosi CA (2002) Coagulation and inflammation in acute lung injury. Thromb Haemost 88(1):17–25PubMed

Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA (2020) Hematological findings and complications of COVID-19. Am J Hematol 95:834–847. https://doi.org/10.1002/ajh.25829CrossRefPubMed

Panigada M, Bottino N, Tagliabue P, Grasselli G, Novembrino C, Chantarangkul V, Pesenti A, Peyvandi F, Tripodi A (2020) Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost 18:1738–1742. https://doi.org/10.1111/jth.14850CrossRefPubMed

Han H, Yang L, Liu R, Liu F, Wu KL, Li J, Liu XH, Zhu CL (2020) Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 58:1116–1120. https://doi.org/10.1515/cclm-2020-0188CrossRefPubMed

Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18(4):844–847. https://doi.org/10.1111/jth.14768CrossRefPubMedPubMedCentral

Giannis D, Ziogas IA, Gianni P (2020) Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol 127:104362. https://doi.org/10.1016/j.jcv.2020.104362CrossRefPubMedPubMedCentral

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q (2020) Clinical and immunologic features in severe and moderate coronavirus disease 2019. J Clin Invest 130(5):2620–2629. https://doi.org/10.1172/JCI137244CrossRefPubMedPubMedCentral

Chauhan AJ, Wiffen LJ, Brown TP (2020) COVID-19: a collision of complement, coagulation and inflammatory pathways. J Thromb Haemost. https://doi.org/10.1111/jth.14981

10.

Fei Y, Tang N, Liu H, Cao W (2020) Coagulation dysfunction: a hallmark in COVID-19. Arch Pathol Lab Med 144:1223–1229. https://doi.org/10.5858/arpa.2020-0324-SACrossRefPubMed

11.

Liu Y, Gao W, Guo W, Guo Y, Shi M, Dong G, Ge Q, Zhu J, Lu J (2020) Prominent coagulation disorder is closely related to inflammatory response and could be as a prognostic indicator for ICU patients with COVID-19. J Thromb Thrombolysis. https://doi.org/10.1007/s11239-020-02174-9

12.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3. Erratum in: Lancet 395(10229):1038. https://doi.org/10.1016/S0140-6736(20)30606-1. Erratum in: Lancet 395(10229):1038. https://doi.org/10.1016/S0140-6736(20)30638-3

13.

Cui S, Chen S, Li X, Liu S, Wang F (2020) Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 18(6):1421–1424. https://doi.org/10.1111/jth.14830CrossRefPubMed

14.

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18(5):1094–1099. https://doi.org/10.1111/jth.14817CrossRefPubMed

15.

Liu Q, Song NC, Zheng ZK, Li JS, Li SK (2020) Laboratory findings and a combined multifactorial approach to predict death in critically ill patients with COVID-19: a retrospective study. Epidemiol Infect 148:e129. https://doi.org/10.1017/S0950268820001442CrossRefPubMed

16.

Jin S, Jin Y, Xu B, Hong J, Yang X (2020) Prevalence and impact of coagulation dysfunction in COVID-19 in China: a meta-analysis [published online ahead of print, 2020 Jul 17]. Thromb Haemost. https://doi.org/10.1055/s-0040-1714369

17.

Liao D, Zhou F, Luo L, Xu M, Wang H, Xia J, Gao Y, Cai L, Wang Z, Yin P, Wang Y, Tang L, Deng J, Mei H, Hu Y (2020) Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. Lancet Haematol S2352-3026(20):30217–30219. https://doi.org/10.1016/S2352-3026(20)30217-9CrossRef

18.

Bao C, Tao X, Cui W, Yi B, Pan T, Young KH, Qian W (2020) SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients. Exp Hematol Oncol 9:16. https://doi.org/10.1186/s40164-020-00172-4CrossRefPubMedPubMedCentral

19.

Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, Zhang Z (2020) D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 18(6):1324–1329. https://doi.org/10.1111/jth.14859CrossRefPubMed

20.

Ranucci M, Ballotta A, Di Dedda U, Bayshnikova E, Dei Poli M, Resta M, Falco M, Albano G, Menicanti L (2020) The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. J Thromb Haemost 18(7):1747–1751. https://doi.org/10.1111/jth.14854CrossRefPubMed

21.

Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, Zhang J, Zhao C (2020) Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis. J Med Virol 92:1902–1914. https://doi.org/10.1002/jmv.25884CrossRefPubMed

22.

Long H, Nie L, Xiang X, Li H, Zhang X, Fu X, Ren H, Liu W, Wang Q, Wu Q (2020) D-dimer and prothrombin time are the significant indicators of severe COVID-19 and poor prognosis. Biomed Res Int 2020:6159720–6159710. https://doi.org/10.1155/2020/6159720CrossRefPubMedPubMedCentral

23.

Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y (2020) Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 180(7):1–11. https://doi.org/10.1001/jamainternmed.2020.0994CrossRefPubMedCentral

24.

Fu YQ, Sun YL, Lu SW, Yang Y, Wang Y, Xu F (2020) Impact of blood analysis and immune function on the prognosis of patients with COVID-19. medRxiv 2020.04.16.20067587. https://doi.org/10.1101/2020.04.16.20067587

Title: Characteristics of coagulation alteration in patients with COVID-19
Authors: Hong-chun Luo
Cheng-yan You
Si-wei Lu
Yue-qiang Fu
Publication date: 01-01-2021
Publisher: Springer Berlin Heidelberg
Keyword: COVID-19
Published in: Annals of Hematology / Issue 1/2021
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04305-x

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Characteristics of coagulation alteration in patients with COVID-19

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasm

Increased incidence of adult T cell leukemia-lymphoma and peripheral T cell lymphoma—not otherwise specified with limited improvement in overall survival: a retrospective analysis using data from the population-based Osaka Cancer Registry

Thrombocytopenia and the effect of platelet transfusions on the occurrence of intracranial hemorrhage in patients with acute leukemia – a nested case-control study

Cyclosporine/methotrexate versus tacrolimus/methotrexate with or without anti-thymocyte globulin as GVHD prophylaxis in adult patients with aplastic anemia

Prevalence of acute liver dysfunction and impact on outcome in critically ill patients with hematological malignancies: a single-center retrospective cohort study

Long-term outcomes of 172 children with severe aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page